These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 32415406)

  • 41. [Ibrutinib: A new drug of B-cell malignancies].
    Thieblemont C
    Bull Cancer; 2015 Jun; 102(6 Suppl 1):S85-90. PubMed ID: 26118882
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ibrutinib-Induced Cardiac Tamponade in Chronic Lymphocytic Leukemia.
    Kidoguchi K; Kubato Y; Nishimura Y; Kizuka-Sano H; Kimura S
    Turk J Haematol; 2021 Feb; 38(1):83-85. PubMed ID: 33161683
    [No Abstract]   [Full Text] [Related]  

  • 43. Severe infections in patients with lymphoproliferative diseases treated with new targeted drugs: A multicentric real-world study.
    Stefania Infante M; Fernández-Cruz A; Núñez L; Carpio C; Jiménez-Ubieto A; López-Jiménez J; Vásquez L; Del Campo R; Romero S; Alonso C; Morillo D; Prat M; Luis Plana J; Villafuerte P; Bastidas G; Bocanegra A; Serna Á; De Nicolás R; Marquet J; Mas-Ochoa C; Cordoba R; García-Suárez J; Comai A; Martín X; Bastos-Oreiro M; Seri C; Navarro-Matilla B; López-Guillermo A; Martínez-López J; Ángel Hernández-Rivas J; Ruiz-Camps I; Grande C;
    Cancer Med; 2021 Nov; 10(21):7629-7640. PubMed ID: 34558211
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL).
    Thompson PA; Burger JA
    Expert Opin Investig Drugs; 2018 Jan; 27(1):31-42. PubMed ID: 29125406
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Systematic review of infectious events with the Bruton tyrosine kinase inhibitor ibrutinib in the treatment of hematologic malignancies.
    Tillman BF; Pauff JM; Satyanarayana G; Talbott M; Warner JL
    Eur J Haematol; 2018 Apr; 100(4):325-334. PubMed ID: 29285806
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis.
    Mato AR; Nabhan C; Thompson MC; Lamanna N; Brander DM; Hill B; Howlett C; Skarbnik A; Cheson BD; Zent C; Pu J; Kiselev P; Goy A; Claxton D; Isaac K; Kennard KH; Timlin C; Landsburg D; Winter A; Nasta SD; Bachow SH; Schuster SJ; Dorsey C; Svoboda J; Barr P; Ujjani CS
    Haematologica; 2018 May; 103(5):874-879. PubMed ID: 29419429
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors.
    Hong D; Rasco D; Veeder M; Luke JJ; Chandler J; Balmanoukian A; George TJ; Munster P; Berlin JD; Gutierrez M; Mita A; Wakelee H; Samakoglu S; Guan S; Dimery I; Graef T; Borazanci E
    Oncology; 2019; 97(2):102-111. PubMed ID: 31230047
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study.
    Gentile M; Morabito F; Del Poeta G; Mauro FR; Reda G; Sportoletti P; Laurenti L; Coscia M; Herishanu Y; Recchia AG; Varettoni M; Murru R; Chiarenza A; Condoluci A; Moia R; Pietrasanta D; Loseto G; Consoli U; Scortechini I; Rossi FM; Zucchetto A; Fraticelli V; Vigna E; Botta C; Tripepi G; Arrigo G; Rago A; Angeletti I; Biagi A; Del Giudice I; Bomben R; Rigolin GM; Rossi D; Di Raimondo F; Gaidano G; Polliack A; Cuneo A; Foà R; Gattei V
    Leukemia; 2021 Jan; 35(1):235-238. PubMed ID: 32286543
    [No Abstract]   [Full Text] [Related]  

  • 49. Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib.
    Awan FT; Schuh A; Brown JR; Furman RR; Pagel JM; Hillmen P; Stephens DM; Woyach J; Bibikova E; Charuworn P; Frigault MM; Hamdy A; Izumi R; Linghu B; Patel P; Wang MH; Byrd JC
    Blood Adv; 2019 May; 3(9):1553-1562. PubMed ID: 31088809
    [TBL] [Abstract][Full Text] [Related]  

  • 50. An oral drug for chronic lymphocytic leukemia.
    Koehler A
    JAAPA; 2020 Feb; 33(2):51-53. PubMed ID: 31990837
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cardiovascular Risk Associated With Ibrutinib Use in Chronic Lymphocytic Leukemia: A Population-Based Cohort Study.
    Abdel-Qadir H; Sabrie N; Leong D; Pang A; Austin PC; Prica A; Nanthakumar K; Calvillo-Argüelles O; Lee DS; Thavendiranathan P
    J Clin Oncol; 2021 Nov; 39(31):3453-3462. PubMed ID: 34464154
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Does Ibrutinib impact outcomes of viral infection by SARS-CoV-2 in mantle cell lymphoma patients?
    Alsuliman T; Faict S; Malard F; Genthon A; Brissot E; Van de Wyngaert Z; Ikhlef S; Banet A; Lapusan S; Sestili S; Corre E; M'hammedi-Bouzina F; Schaeffer L; Legrand O; Dulery R; Mohty M; Marjanovic Z
    Curr Res Transl Med; 2021 Jan; 69(1):103273. PubMed ID: 33460953
    [No Abstract]   [Full Text] [Related]  

  • 53. Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
    Coutré SE; Furman RR; Flinn IW; Burger JA; Blum K; Sharman J; Jones J; Wierda W; Zhao W; Heerema NA; Johnson AJ; Tran A; Zhou C; Bilotti E; James DF; Byrd JC; O'Brien S
    Clin Cancer Res; 2017 Mar; 23(5):1149-1155. PubMed ID: 28073846
    [No Abstract]   [Full Text] [Related]  

  • 54. Ibrutinib for the treatment of chronic lymphocytic leukemia.
    Deodato M; Frustaci AM; Zamprogna G; Cairoli R; Montillo M; Tedeschi A
    Expert Rev Hematol; 2019 May; 12(5):273-284. PubMed ID: 30916599
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Infectious Complications of Tyrosine Kinase Inhibitors in Hematological Malignancies.
    Kin A; Schiffer CA
    Infect Dis Clin North Am; 2020 Jun; 34(2):245-256. PubMed ID: 32444010
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effective upfront treatment with low-dose ibrutinib for a patient with B cell prolymphocytic leukemia.
    Oka S; Ono K; Nohgawa M
    Invest New Drugs; 2020 Oct; 38(5):1598-1600. PubMed ID: 31965420
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ibrutinib-induced polyneuropathy: A case report.
    Cömert P; Albayrak M; Yıldız A; Şahin O; Öztürk HB; Reis Aras M
    J Oncol Pharm Pract; 2020 Sep; 26(6):1501-1504. PubMed ID: 32028841
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The role of ibrutinib in COVID-19 hyperinflammation: A case report.
    Maynard S; Ros-Soto J; Chaidos A; Innes A; Paleja K; Mirvis E; Buti N; Sharp H; Palanicawandar R; Milojkovic D
    Int J Infect Dis; 2021 Apr; 105():274-276. PubMed ID: 33607304
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ibrutinib-Induced Skin Rash.
    Kirar S; Gogia A; Gupta R; Mallick S
    Turk J Haematol; 2021 Feb; 38(1):81-83. PubMed ID: 33053966
    [No Abstract]   [Full Text] [Related]  

  • 60. Bruton Tyrosine Kinase Inhibitors: Present and Future.
    Burger JA
    Cancer J; 2019; 25(6):386-393. PubMed ID: 31764119
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.